<DOC>
	<DOCNO>NCT01101906</DOCNO>
	<brief_summary>This randomize , placebo-controlled , double-blind phase 2 study OSI-906 placebo continuous 150 mg twice daily ( BID ) dose .</brief_summary>
	<brief_title>A Randomized , Placebo-controlled , Double-blind Phase 2 Study With OSI-906 Patients With Advanced HCC</brief_title>
	<detailed_description>Adult patient advance HCC previously treat sorafenib randomize 2:1 receive either single agent OSI-906 placebo</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>Histologically confirm diagnosis advance HCC . Clinical diagnosis American Association Study Liver Diseases ( AASLD ) criterion cirrhotic patient acceptable . For patient without cirrhosis histological confirmation mandatory Patients must receive prior systemic treatment advance HCC sorafenib confirm disease progression discontinue sorafenib due drug relate toxicity Patient receive last dose sorafenib least 14 day prior randomization Patient recover sorafenib investigational agent relate toxicity ≤ grade 2 Measurable disease accord RECIST ( version 1.1 ) Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) 0 1 ChildPugh Status A B ( 7 ) Barcelona Clinic Liver Cancer ( BCLC ) stage B/C Previous local therapy ( eg , surgery , radiation therapy , hepatic arterial therapy , chemoembolization , radiofrequency ablation , percutaneous ethanol injection , cryoablation ) permit ≥ 21 day randomization Fasting glucose ≤ 150 mg/dL ( 8.3 mmol/L ) . Concurrent use noninsulinotropic oral antihyperglycemic therapy permit dose stable ≥ 4 week time randomization Following laboratory parameter ( determined laboratory ) : Platelets ≥ 60 x 10^9/L Hemoglobin ≥ 8.5 g/dL Absolute neutraphil count ( ANC ) ≥ 1.5 x 10^9/L Potassium within normal limit ( supplementation may use ) Partial thrombopastin time ( PTT ) ≤ 2.3 x Upper Limit Normal ( ULN ) Magnesium within normal limit ( supplementation may use ) Calcium within normal limit ( supplementation may use ) Adequate organ function ( HCC population ) : Liver function test ( LFT ) ≤ 5 x ULN Albumin ≥ 2.8 g/dL Total bilirubin ≤ 2.8 mg/dL Creatinine ≤ 1.5 x ULN International normalize ratio ( INR ) ≤ 2.3 Estimated life expectancy ≥ 12 week base investigator assessment recent change laboratory value , performance status , clinical criterion Patients , male female , reproductive potential ( ie , menopausal less 1 year surgically sterilize ) must agree practice effective contraceptive measure throughout study . Women childbearing potential must provide negative pregnancy test ( serum urine ) within 14 day prior randomization Patients must provide write informed consent participate study Prior radiation therapy permit provided patient recover acute , toxic effect radiotherapy prior randomization . A minimum 21 day must elapse end radiotherapy randomization ; Prior surgery permit provide surgery do ≤ 28 day prior randomization adequate wound heal occur prior randomization ChildPugh B ( 8 9 ) C Patients candidate potentially curative intervention ( ie , surgical resection transplantation ) Type 1 diabetes mellitus Type 2 diabetes mellitus currently require insulinotropic insulin therapy Prior insulinlike growth factor 1 receptor ( IGF1R ) therapy Patients require interferon Patients uncontrolled symptomatic ascites Prior investigational agent within 21 day prior randomization History poorly control gastrointestinal disorder could affect absorption study drug ( eg , Crohn 's disease , ulcerative colitis , etc ) History organ allograft include liver transplant Malignancy HCC within past 3 year : Exceptions : resect basal cell squamous cell carcinoma skin , cure situ cervical carcinoma , cure ductal carcinoma situ breast , and/or cure superficial bladder cancer History ( within last 6 month ) significant cardiovascular disease unless disease wellcontrolled . Significant cardiac disease include second/third degree heart block ; clinically significant ischemic heart disease ; superior vena cava ( SVC ) syndrome ; poorly control hypertension ; congestive heart failure New York Heart Association ( NYHA ) Class II worse ( slight limitation physical activity ; comfortable rest , ordinary physical activity result fatigue , palpitation , dyspnea ) History arrhythmia ( multifocal premature ventricular contraction [ PVCs ] , bigeminy , trigeminy , ventricular tachycardia , uncontrolled atrial fibrillation ) symptomatic require treatment ( ≥ grade 3 ) , leave bundle branch block ( LBBB ) , asymptomatic sustain ventricular tachycardia allow . Patients atrial fibrillation control medication exclude QTcF interval screen ≥ 450 msec Use drug know risk cause Torsades de Pointes ( TdP ) ( 'Torsades List ' www.azcert.org/medicalpros/druglists/by category.cfm ) prohibit within 14 day prior randomization Use potent CYP1A2 inhibitor ciprofloxacin fluvoxamine . Other less potent CYP1A2 inhibitors/inducers exclude History cerebrovascular accident ( CVA ) within 6 month prior randomization result ongoing neurologic instability Active infection serious underlie medical condition ( include type active seizure disorder within 12 month prior randomization ) would impair ability patient receive study drug History human immunodeficiency virus ( HIV ) infection acquire immune deficiency syndrome ( AIDS ) relate illness serious acute chronic illness History psychiatric neurologic condition might impair patient 's ability understand comply requirement study provide inform consent Pregnant breastfeeding female Symptomatic brain metastasis stable , require steroid , potentially life threatening , require radiation within 28 day prior randomization ; and/or History allergic reaction attribute compound similar chemical biologic composition study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>OSI-906</keyword>
	<keyword>HCC</keyword>
	<keyword>Hepatocellular Carcinoma</keyword>
</DOC>